Research ArticleClinical Studies
Open Access

Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer

RYO SATO, YUKIHIRO YOSHIMI, TETSUHARU NISHIO, YU MATSUNAGA and RIKIYA MATSUMOTO
In Vivo May 2026, 40 (3) 1628-1636; DOI: https://doi.org/10.21873/invivo.14313

Article Figures & Data

Figures

  • Figure 1.
    Figure 1.

    Overall survival (OS) according to the occurrence of grade ≥3 neutropenia during the first cycle (Cycle 1) of cabazitaxel treatment. Kaplan–Meier curves comparing overall survival between patients who developed grade ≥3 neutropenia during Cycle 1 and those who did not. Survival distributions were compared using the log-rank test.

  • Figure 2.
    Figure 2.

    Progression-free survival (PFS) according to the occurrence of grade ≥3 neutropenia during the first cycle (Cycle 1) of cabazitaxel treatment. Kaplan–Meier curves comparing PFS between patients who developed grade ≥3 neutropenia during Cycle 1 and those who did not. Survival distributions were compared using the log-rank test.

Tables

  • Table I.
  • Table II.
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools
Reprints and Permissions
Risk Factors and Clinical Significance of Grade ≥3 Neutropenia During the First Cycle of Cabazitaxel Therapy With Primary Pegfilgrastim Prophylaxis in Metastatic Castration-resistant Prostate Cancer
RYO SATO, YUKIHIRO YOSHIMI, TETSUHARU NISHIO, YU MATSUNAGA, RIKIYA MATSUMOTO
In Vivo May 2026, 40 (3) 1628-1636; DOI: 10.21873/invivo.14313
Twitter logo Facebook logo Mendeley logo

Jump to section

Keywords